vs
Side-by-side financial comparison of FORRESTER RESEARCH, INC. (FORR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
FORRESTER RESEARCH, INC. is the larger business by last-quarter revenue ($101.1M vs $70.6M, roughly 1.4× Viridian Therapeutics, Inc.\DE). FORRESTER RESEARCH, INC. runs the higher net margin — -33.5% vs -49.0%, a 15.5% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -6.5%). FORRESTER RESEARCH, INC. produced more free cash flow last quarter ($-4.3M vs $-84.7M).
Forrester Research, Inc. is a research and advisory firm working in research, consulting and events. Forrester’s clients include large global business, technology and consumer enterprises. The firm is headquartered in Cambridge, MA.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
FORR vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $101.1M | $70.6M |
| Net Profit | $-33.9M | $-34.6M |
| Gross Margin | 56.7% | — |
| Operating Margin | -36.6% | -56.7% |
| Net Margin | -33.5% | -49.0% |
| Revenue YoY | -6.5% | 81958.1% |
| Net Profit YoY | -7941.4% | 54.9% |
| EPS (diluted) | $-1.75 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $101.1M | — | ||
| Q3 25 | $94.3M | $70.6M | ||
| Q2 25 | $111.7M | — | ||
| Q1 25 | $89.9M | — | ||
| Q4 24 | $108.0M | — | ||
| Q3 24 | $102.5M | — | ||
| Q2 24 | $121.8M | — | ||
| Q1 24 | $100.1M | — |
| Q4 25 | $-33.9M | — | ||
| Q3 25 | $-2.1M | $-34.6M | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $-87.3M | — | ||
| Q4 24 | $432.0K | — | ||
| Q3 24 | $-5.8M | — | ||
| Q2 24 | $6.3M | — | ||
| Q1 24 | $-6.7M | — |
| Q4 25 | 56.7% | — | ||
| Q3 25 | 60.0% | — | ||
| Q2 25 | 55.5% | — | ||
| Q1 25 | 55.9% | — | ||
| Q4 24 | 58.8% | — | ||
| Q3 24 | 60.5% | — | ||
| Q2 24 | 57.3% | — | ||
| Q1 24 | 54.9% | — |
| Q4 25 | -36.6% | — | ||
| Q3 25 | 4.7% | -56.7% | ||
| Q2 25 | 6.2% | — | ||
| Q1 25 | -97.5% | — | ||
| Q4 24 | -0.5% | — | ||
| Q3 24 | -0.7% | — | ||
| Q2 24 | 9.3% | — | ||
| Q1 24 | -9.3% | — |
| Q4 25 | -33.5% | — | ||
| Q3 25 | -2.3% | -49.0% | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | -97.1% | — | ||
| Q4 24 | 0.4% | — | ||
| Q3 24 | -5.7% | — | ||
| Q2 24 | 5.2% | — | ||
| Q1 24 | -6.7% | — |
| Q4 25 | $-1.75 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $0.20 | — | ||
| Q1 25 | $-4.62 | — | ||
| Q4 24 | $0.02 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $0.33 | — | ||
| Q1 24 | $-0.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $126.5M | $503.0M |
| Total Assets | $404.0M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | — | ||
| Q3 25 | $65.1M | $490.9M | ||
| Q2 25 | $67.8M | — | ||
| Q1 25 | $75.6M | — | ||
| Q4 24 | $56.1M | — | ||
| Q3 24 | $62.8M | — | ||
| Q2 24 | $58.9M | — | ||
| Q1 24 | $61.4M | — |
| Q4 25 | $126.5M | — | ||
| Q3 25 | $157.7M | $503.0M | ||
| Q2 25 | $159.5M | — | ||
| Q1 25 | $147.4M | — | ||
| Q4 24 | $229.5M | — | ||
| Q3 24 | $234.3M | — | ||
| Q2 24 | $237.1M | — | ||
| Q1 24 | $230.9M | — |
| Q4 25 | $404.0M | — | ||
| Q3 25 | $414.2M | $577.1M | ||
| Q2 25 | $436.0M | — | ||
| Q1 25 | $439.8M | — | ||
| Q4 24 | $503.9M | — | ||
| Q3 24 | $505.3M | — | ||
| Q2 24 | $524.2M | — | ||
| Q1 24 | $555.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.2M | $-84.6M |
| Free Cash FlowOCF − Capex | $-4.3M | $-84.7M |
| FCF MarginFCF / Revenue | -4.2% | -120.1% |
| Capex IntensityCapex / Revenue | 1.1% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $18.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $1.2M | $-84.6M | ||
| Q2 25 | $-3.6M | — | ||
| Q1 25 | $26.7M | — | ||
| Q4 24 | $-1.8M | — | ||
| Q3 24 | $264.0K | — | ||
| Q2 24 | $-2.9M | — | ||
| Q1 24 | $611.0K | — |
| Q4 25 | $-4.3M | — | ||
| Q3 25 | $524.0K | $-84.7M | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $26.1M | — | ||
| Q4 24 | $-2.5M | — | ||
| Q3 24 | $-223.0K | — | ||
| Q2 24 | $-3.7M | — | ||
| Q1 24 | $-815.0K | — |
| Q4 25 | -4.2% | — | ||
| Q3 25 | 0.6% | -120.1% | ||
| Q2 25 | -3.8% | — | ||
| Q1 25 | 29.0% | — | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -0.2% | — | ||
| Q2 24 | -3.1% | — | ||
| Q1 24 | -0.8% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.7% | 0.2% | ||
| Q2 25 | 0.5% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.93× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -0.46× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
VRDN
Segment breakdown not available.
